Reference(s)
Click here to return to the Reference Table

Cancer type: Pancreas/Gall Bladder


HGF/SF expression

Reference Number: 109
La Rosa, S., Uccella, S., Capella, C., Erba, S. & Sessa, F. Localization of Hepatocyte Growth Factor and Its Receptor met in Endocrine Cells and Related Tumors of the Gut and Pancreas: An Immunohistochemical Study. Endocr Pathol 11, 315-329. (2000).
PubMed link      E-mail link

Reference Number: 364
Shimura H, Date K, Matsumoto K, Nakamura T, Tanaka M. Induction of invasive growth in a gallbladder cancer cell line by hepatocyte growth factor in vitro. Jpn J Cancer Res. 86, 662-9 (1995)
PubMed link      E-mail link

Reference Number: 366
Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene. 17, 3045-54 (1998)
PubMed link      E-mail link

Reference Number: 393
Murakami M, Nagai E, Mizumoto K, Saimura M, Ohuchida K, Inadome N, Matsumoto K, Nakamura T, Maemondo M, Nukiwa T, Tanaka M. Suppression of metastasis of human pancreatic cancer to the liver by transportal injection of recombinant adenoviral NK4 in nude mice. Int J Cancer. 117, 160-5 (2005)
PubMed link      E-mail link

Reference Number: 415
Li H, Shimura H, Aoki Y, Date K, Matsumoto K, Nakamura T, Tanaka M. Hepatocyte growth factor stimulates the invasion of gallbladder carcinoma cell lines in vitro. Clin Exp Metastasis. 16, 74-82 (1998)
PubMed link      E-mail link

Reference Number: 497
Matsumoto K, Date K, Shimura H, Nakamura T. Acquisition of invasive phenotype in gallbladder cancer cells via mutual interaction of stromal fibroblasts and cancer cells as mediated by hepatocyte growth factor. Jpn J Cancer Res. 87, 702-10 (1996)
PubMed link      E-mail link

Reference Number: 502
Bauer TW, Somcio RJ, Fan F, Liu W, Johnson M, Lesslie DP, Evans DB, Gallick GE, Ellis LM. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther. 5, 1676-82 (2006)
PubMed link      E-mail link

Reference Number: 597
Ide T, Kitajima Y, Miyoshi A, Ohtsuka T, Mitsuno M, Ohtaka K, Miyazaki K. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann Surg Oncol. 14, 2600-7 (2007)
PubMed link      E-mail link

Reference Number: 598
Tanaka T, Shimura H, Sasaki T, Narumi K, Maemondo M, Nukiwa T, Matsumoto K, Nakamura T, Ikeda S. Gallbladder cancer treatment using adenovirus expressing the HGF/NK4 gene in a peritoneal implantation model. Cancer Gene Ther. 11, 431-40 (2004)
PubMed link      E-mail link

Reference Number: 599
Hasina R, Matsumoto K, Matsumoto-Taniura N, Kato I, Sakuda M, Nakamura T. Autocrine and paracrine motility factors and their involvement in invasiveness in a human oral carcinoma cell line. Br J Cancer. 80, 1708-17 (1999)
PubMed link      E-mail link

Reference Number: 609
Matsushita A, Götze T, Korc M. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res. 67, 10309-16 (2007)
PubMed link      E-mail link

Reference Number: 648
Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68, 4360-8 (2008)
PubMed link      E-mail link

Reference Number: 650
Kitajima Y, Ide T, Ohtsuka T, Miyazaki K. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci. 99, 1341-7 (2008)
PubMed link      E-mail link

Reference Number: 660
Singh PK, Behrens ME, Eggers JP, Cerny RL, Bailey JM, Shanmugam K, Gendler SJ, Bennett EP, Hollingsworth MA. Phosphorylation of MUC1 by met modulates interaction with p53 and MMP1 expression. J Biol Chem. 2008 Jul 14. [Epub ahead of print]
PubMed link      E-mail link

Reference Number: 672
Cruz-Monserrate Z, O'Connor KL. Integrin alpha 6 beta 4 promotes migration, invasion through Tiam1 upregulation, and subsequent Rac activation. Neoplasia. 10, 408-17 (2008)
PubMed link      E-mail link

Reference Number: 718
Chan GK, Lutterbach BA, Pan BS, Kariv I, Szewczak AA. High-throughput analysis of HGF-stimulated cell scattering. J Biomol Screen. 13, 847-54 (2008) Epub 2008 Sep 23
PubMed link      E-mail link

Reference Number: 722
Justinger C, Schlüter C, Oliviera-Frick V, Kopp B, Rubie C, Schilling MK. Increased growth factor expression after hepatic and pancreatic resection. Oncol Rep. 20, 1527-31 (2008)
PubMed link      E-mail link

Reference Number: 933
Tan XG, Yang ZL. Expression of Ezrin, HGF, C-met in pancreatic cancer and non-cancerous pancreatic tissues of rats. Hepatobiliary Pancreat Dis Int. 9, 639-44 (2010)
PubMed link      E-mail link

Reference Number: 937
Argast GM, Mercado P, Mulford IJ, O'Connor M, Keane DM, Shaaban S, Epstein DM, Pachter JA, Kan JL. Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-ß enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. Cells Tissues Organs. 193, 114-32 (2011)
PubMed link      E-mail link

Reference Number: 1223
Yang L, Guo T, Jiang S, Yang Z. Expression of ezrin, HGF and c-met and its clinicopathological significance in the benign and malignant lesions of the gallbladder. Hepatogastroenterology. 59, 1769-75 (2012)
PubMed link      E-mail link

Reference Number: 1534
Oyanagi J, Kojima N, Sato H, Higashi S, Kikuchi K, Sakai K, Matsumoto K, Miyazaki K. Inhibition of transforming growth factor-ß signaling potentiates tumor cell invasion into collagen matrix induced by fibroblast-derived hepatocyte growth factor. Exp Cell Res. 326, 267-79 (2014)
PubMed link      E-mail link

Reference Number: 1608
Sun YP, Zhang BL, Duan JW, Wu HH, Wang BQ, Yu ZP, Yang WJ, Shan YF, Zhou MT, Zhang QY. Effect of NK4 transduction in bone marrow-derived mesenchymal stem cells on biological characteristics of pancreatic cancer cells. Int J Mol Sci. 15, 3729-45 (2014)
PubMed link      E-mail link

Reference Number: 1609
Patel MB, Pothula SP, Xu Z, Lee AK, Goldstein D, Pirola RC, Apte MV, Wilson JS. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer. Carcinogenesis. 35, 1891-900 (2014)
PubMed link      E-mail link

Reference Number: 1871
Carpenter BL, Chen M, Knifley T, Davis KA, Harrison SM, Stewart RL, O'Connor KL. Integrin a6ß4 Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF). J Biol Chem. 290, 27228-38 (2015)
PubMed link      E-mail link

Met expression

Reference Number: 109
La Rosa, S., Uccella, S., Capella, C., Erba, S. & Sessa, F. Localization of Hepatocyte Growth Factor and Its Receptor met in Endocrine Cells and Related Tumors of the Gut and Pancreas: An Immunohistochemical Study. Endocr Pathol 11, 315-329. (2000).
PubMed link      E-mail link

Reference Number: 383
Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 206, 356-65 (2005)
PubMed link      E-mail link

Reference Number: 391
Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res. 65, 7775-81 (2005)
PubMed link      E-mail link

Reference Number: 392
Leelawat K, Ohuchida K, Mizumoto K, Mahidol C, Tanaka M. All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 224, 303-10 (2005)
PubMed link      E-mail link

Reference Number: 501
Ide T, Kitajima Y, Miyoshi A, Ohtsuka T, Mitsuno M, Ohtaka K, Koga Y, Miyazaki K. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int J Cancer. 119, 2750-9 (2006)
PubMed link      E-mail link

Reference Number: 502
Bauer TW, Somcio RJ, Fan F, Liu W, Johnson M, Lesslie DP, Evans DB, Gallick GE, Ellis LM. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther. 5, 1676-82 (2006)
PubMed link      E-mail link

Reference Number: 503
Yu J, Ohuchida K, Mizumoto K, Ishikawa N, Ogura Y, Yamada D, Egami T, Fujita H, Ohashi S, Nagai E, Tanaka M. Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer. World J Gastroenterol. 12, 3878-82 (2006)
PubMed link      E-mail link

Reference Number: 597
Ide T, Kitajima Y, Miyoshi A, Ohtsuka T, Mitsuno M, Ohtaka K, Miyazaki K. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann Surg Oncol. 14, 2600-7 (2007)
PubMed link      E-mail link

Reference Number: 609
Matsushita A, Götze T, Korc M. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res. 67, 10309-16 (2007)
PubMed link      E-mail link

Reference Number: 628
Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 14, 3629-37 (2007)
PubMed link      E-mail link

Reference Number: 648
Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68, 4360-8 (2008)
PubMed link      E-mail link

Reference Number: 660
Singh PK, Behrens ME, Eggers JP, Cerny RL, Bailey JM, Shanmugam K, Gendler SJ, Bennett EP, Hollingsworth MA. Phosphorylation of MUC1 by met modulates interaction with p53 and MMP1 expression. J Biol Chem. 2008 Jul 14. [Epub ahead of print]
PubMed link      E-mail link

Reference Number: 680
Lam MM, Swanson PE, Upton MP, Yeh MM. Ovarian-type stroma in hepatobiliary cystadenomas and pancreatic mucinous cystic neoplasms: an immunohistochemical study. Am J Clin Pathol. 129, 211-8 (2008)
PubMed link      E-mail link

Reference Number: 919
Hill KS, Lorinczi M, Elferink LA. Altered down regulation of the receptor tyrosine kinase met in pancreatic adenocarcinoma cells. J Exp Ther Oncol. 8, 297-312 (2010)
PubMed link      E-mail link

Reference Number: 933
Tan XG, Yang ZL. Expression of Ezrin, HGF, C-met in pancreatic cancer and non-cancerous pancreatic tissues of rats. Hepatobiliary Pancreat Dis Int. 9, 639-44 (2010)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 994
Zhu GH, Huang C, Qiu ZJ, Liu J, Zhang ZH, Zhao N, Feng ZZ, Lv XH. Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma. Dig Dis Sci. 56, 1090-8 (2011)
PubMed link      E-mail link

Reference Number: 1044
Zhou J, Hu L, Yu Z, Zheng J, Yang D, Bouvet M, Hoffman RM. Marker expression in circulating cancer cells of pancreatic cancer patients. J Surg Res. 171, 631-6 (2011)
PubMed link      E-mail link

Reference Number: 1068
Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, Pasca di Magliano M, Simeone DM. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 141, 2218-2227.e5 (2011)
PubMed link      E-mail link

Reference Number: 1223
Yang L, Guo T, Jiang S, Yang Z. Expression of ezrin, HGF and c-met and its clinicopathological significance in the benign and malignant lesions of the gallbladder. Hepatogastroenterology. 59, 1769-75 (2012)
PubMed link      E-mail link

Reference Number: 1270
Hill KS, Gaziova I, Harrigal L, Guerra YA, Qiu S, Sastry SK, Arumugam T, Logsdon CD, Elferink LA. Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer. PLoS One. 7, e40420 (2012)
PubMed link      E-mail link

Reference Number: 1408
Avan A1, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell RJ, Lagerweij T, Van Tellingen O, Campani D, Fuchs D, Verheul HM, Schuurhuis GJ, Boggi U, Peters GJ, Würdinger T, Giovannetti E. Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. Cancer Res. 73, 6745-56 (2013)
PubMed link      E-mail link

Reference Number: 1409
Ucar DA1, Magis AT, He DH, Lawrence NJ, Sebti SM, Kurenova E, Zajac-Kaye M, Zhang J, Hochwald SN. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo. Anticancer Agents Med Chem. 13, 595-602 (2013)
PubMed link      E-mail link

Reference Number: 1567
Nones K, Waddell N, Song S, Patch AM, Miller D, Johns A, Wu J, Kassahn KS, Wood D, Bailey P, Fink L, Manning S, Christ AN, Nourse C, Kazakoff S, Taylor D, Leonard C, Chang DK, Jones MD, Thomas M, Watson C, Pinese M, Cowley M, Rooman I, Pajic M; APGI, Butturini G, Malpaga A, Corbo V, Crippa S, Falconi M, Zamboni G, Castelli P, Lawlor RT, Gill AJ, Scarpa A, Pearson JV, Biankin AV, Grimmond SM. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int J Cancer. 135, 1110-8 (2014)
PubMed link      E-mail link

Reference Number: 1609
Patel MB, Pothula SP, Xu Z, Lee AK, Goldstein D, Pirola RC, Apte MV, Wilson JS. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer. Carcinogenesis. 35, 1891-900 (2014)
PubMed link      E-mail link

Reference Number: 1629
Zhou W, Jubb AM, Lyle K, Xiao Q, Ong CC, Desai R, Fu L, Gnad F, Song Q, Haverty PM, Aust D, Grützmann R, Romero M, Totpal K, Neve RM, Yan Y, Forrest WF, Wang Y, Raja R, Pilarsky C, de Jesus-Acosta A, Belvin M, Friedman LS, Merchant M, Jaffee EM, Zheng L, Koeppen H, Hoeflich KP. PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. J Pathol. 234, 502-13 (2014)
PubMed link      E-mail link

Reference Number: 1736
Yan HH, Jung KH, Son MK, Fang Z, Kim SJ, Ryu YL, Kim J, Kim MH, Hong SS. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. Oncotarget. 5, 9150-68 (2014)
PubMed link      E-mail link

Reference Number: 1823
Noguchi K, Eguchi H, Konno M, Kawamoto K, Nishida N, Koseki J, Wada H, Marubashi S, Nagano H, Doki Y, Mori M, Ishii H. Susceptibility of pancreatic cancer stem cells to reprogramming. Cancer Sci. 106, 1182-7 (2015)
PubMed link      E-mail link

Reference Number: 1896
Desai SS, Kharade SS, Parekh VI, Iyer S, Agarwal SK. Pro-oncogenic Roles of HLXB9 Protein in Insulinoma Cells through Interaction with Nono Protein and Down-regulation of the c-Met Inhibitor Cblb (Casitas B-lineage Lymphoma b). J Biol Chem. 290, 25595-608 (2015)
PubMed link      E-mail link

Reference Number: 1897
Modali SD, Parekh VI, Kebebew E, Agarwal SK. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors. Mol Endocrinol. 29, 224-37 (2015)
PubMed link      E-mail link

Poor Prognosis

Reference Number: 919
Hill KS, Lorinczi M, Elferink LA. Altered down regulation of the receptor tyrosine kinase met in pancreatic adenocarcinoma cells. J Exp Ther Oncol. 8, 297-312 (2010)
PubMed link      E-mail link

Reference Number: 1223
Yang L, Guo T, Jiang S, Yang Z. Expression of ezrin, HGF and c-met and its clinicopathological significance in the benign and malignant lesions of the gallbladder. Hepatogastroenterology. 59, 1769-75 (2012)
PubMed link      E-mail link

Mutation of Met

In vitro studies

Reference Number: 110
Kiehne, K., Herzig, K. H. & Folsch, U. R. c-met expression in pancreatic cancer and effects of hepatocyte growth factor on pancreatic cancer cell growth. Pancreas 15, 35-40. (1997).
PubMed link      E-mail link

Reference Number: 111
Li, H. et al. Hepatocyte growth factor stimulates the invasion of gallbladder carcinoma cell lines in vitro. Clin Exp Metastasis 16, 74-82. (1998).
PubMed link      E-mail link

Reference Number: 112
Ohba, N., Funatomi, H., Seki, T., Makino, R. & Mitamura, K. Hepatocyte growth factor stimulates cell growth and enhances the expression of transforming growth factor alpha mRNA in AsPC-1 human pancreatic cancer cells. J Gastroenterol 34, 498-504. (1999).
PubMed link      E-mail link

Reference Number: 113
Qian, L. W. et al. Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production. Cancer Lett 190, 105-12 (2003).
PubMed link      E-mail link

Reference Number: 364
Shimura H, Date K, Matsumoto K, Nakamura T, Tanaka M. Induction of invasive growth in a gallbladder cancer cell line by hepatocyte growth factor in vitro. Jpn J Cancer Res. 86, 662-9 (1995)
PubMed link      E-mail link

Reference Number: 391
Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res. 65, 7775-81 (2005)
PubMed link      E-mail link

Reference Number: 392
Leelawat K, Ohuchida K, Mizumoto K, Mahidol C, Tanaka M. All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 224, 303-10 (2005)
PubMed link      E-mail link

Reference Number: 415
Li H, Shimura H, Aoki Y, Date K, Matsumoto K, Nakamura T, Tanaka M. Hepatocyte growth factor stimulates the invasion of gallbladder carcinoma cell lines in vitro. Clin Exp Metastasis. 16, 74-82 (1998)
PubMed link      E-mail link

Reference Number: 501
Ide T, Kitajima Y, Miyoshi A, Ohtsuka T, Mitsuno M, Ohtaka K, Koga Y, Miyazaki K. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int J Cancer. 119, 2750-9 (2006)
PubMed link      E-mail link

Reference Number: 599
Hasina R, Matsumoto K, Matsumoto-Taniura N, Kato I, Sakuda M, Nakamura T. Autocrine and paracrine motility factors and their involvement in invasiveness in a human oral carcinoma cell line. Br J Cancer. 80, 1708-17 (1999)
PubMed link      E-mail link

Reference Number: 609
Matsushita A, Götze T, Korc M. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res. 67, 10309-16 (2007)
PubMed link      E-mail link

Reference Number: 648
Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68, 4360-8 (2008)
PubMed link      E-mail link

Reference Number: 650
Kitajima Y, Ide T, Ohtsuka T, Miyazaki K. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci. 99, 1341-7 (2008)
PubMed link      E-mail link

Reference Number: 718
Chan GK, Lutterbach BA, Pan BS, Kariv I, Szewczak AA. High-throughput analysis of HGF-stimulated cell scattering. J Biomol Screen. 13, 847-54 (2008) Epub 2008 Sep 23
PubMed link      E-mail link

Reference Number: 840
Xu D, Matsuo Y, Ma J, Koide S, Ochi N, Yasuda A, Funahashi H, Okada Y, Takeyama H. Cancer cell-derived IL-1a promotes HGF secretion by stromal cells and enhances metastatic potential in pancreatic cancer cells. J Surg Oncol. 102, 469-77 (2010)
PubMed link      E-mail link

Reference Number: 937
Argast GM, Mercado P, Mulford IJ, O'Connor M, Keane DM, Shaaban S, Epstein DM, Pachter JA, Kan JL. Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-ß enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. Cells Tissues Organs. 193, 114-32 (2011)
PubMed link      E-mail link

Reference Number: 957
Watanabe S, Kishimoto T, Yokosuka O. Hepatocyte growth factor inhibits anoikis of pancreatic carcinoma cells through phosphatidylinositol 3-kinase pathway. Pancreas. 40, 608-14 (2011)
PubMed link      E-mail link

Animal models

Reference Number: 114
Jeffers, M., Rong, S. & Vande Woude, G. F. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16, 1115-25 (1996).
PubMed link      E-mail link

Reference Number: 115
Jeffers, M. et al. Hepatocyte growth factor/scatter factor-Met signaling induces proliferation, migration, and morphogenesis of pancreatic oval cells. Cell Growth Differ 7, 1805-13 (1996).
PubMed link      E-mail link

Reference Number: 391
Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res. 65, 7775-81 (2005)
PubMed link      E-mail link

Reference Number: 393
Murakami M, Nagai E, Mizumoto K, Saimura M, Ohuchida K, Inadome N, Matsumoto K, Nakamura T, Maemondo M, Nukiwa T, Tanaka M. Suppression of metastasis of human pancreatic cancer to the liver by transportal injection of recombinant adenoviral NK4 in nude mice. Int J Cancer. 117, 160-5 (2005)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 1317
Sennino B, Ishiguro-Oonuma T, Schriver BJ, Christensen JG, McDonald DM. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res. 73, 3692-703 (2013)
PubMed link      E-mail link

Therapeutic Development

Reference Number: 116
Maehara, N. et al. Gene transduction of NK4, HGF antagonist, inhibits in vitro invasion and in vivo growth of human pancreatic cancer. Clin Exp Metastasis 19, 417-26 (2002).
PubMed link      E-mail link

Reference Number: 117
Saimura, M. et al. Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. Clin Cancer Res 8, 3243-9 (2002).
PubMed link      E-mail link

Reference Number: 118
Tomioka, D. et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 61, 7518-24 (2001).
PubMed link      E-mail link

Reference Number: 289
Lai RX, Yuan SZ, Nakamura T. [Article in Chinese] [Effect of Transferred NK4 Gene on Biological Characteristics of Human Pancreatic Cancer Cell Line SW1990.] Ai Zheng 23, 1134-8 (2004)
PubMed link      E-mail link

Reference Number: 290
Kushibiki T, Matsumoto K, Nakamura T, Tabata Y. Suppression of the progress of disseminated pancreatic cancer cells by NK4 plasmid DNA released from cationized gelatin microspheres. Pharm Res 21, 1109-18 (2004)
PubMed link      E-mail link

Reference Number: 296
Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E, Matsumoto K, Nakamura T, Tanaka M. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 64, 3215-22 (2004)
PubMed link      E-mail link

Reference Number: 297
Tanaka T, Shimura H, Sasaki T, Narumi K, Maemondo M, Nukiwa T, Matsumoto K, Nakamura T, Ikeda S. Gallbladder cancer treatment using adenovirus expressing the HGF/NK4 gene in a peritoneal implantation model. Cancer Gene Ther 11, 431-40 (2004)
PubMed link      E-mail link

Reference Number: 366
Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene. 17, 3045-54 (1998)
PubMed link      E-mail link

Reference Number: 389
Ogura Y, Mizumoto K, Nagai E, Murakami M, Inadome N, Saimura M, Matsumoto K, Nakamura T, Maemondo M, Nukiwa T, Tanaka M. Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival. Cancer Gene Ther. 13, 520-9 (2006)
PubMed link      E-mail link

Reference Number: 390
Saito T, Tomida M. Generation of inhibitory DNA aptamers against human hepatocyte growth factor. DNA Cell Biol. 24, 624-33 (2005)
PubMed link      E-mail link

Reference Number: 391
Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res. 65, 7775-81 (2005)
PubMed link      E-mail link

Reference Number: 628
Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 14, 3629-37 (2007)
PubMed link      E-mail link

Reference Number: 648
Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68, 4360-8 (2008)
PubMed link      E-mail link

Reference Number: 673
Egami T, Ohuchida K, Mizumoto K, Onimaru M, Toma H, Nishio S, Nagai E, Matsumoto K, Nakamura T, Tanaka M. Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake. Clin Cancer Res. 14, 1859-67 (2008)
PubMed link      E-mail link

Reference Number: 838
Bagai R, Fan W, Ma PC. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs. 13, 404-14 (2010)
PubMed link      E-mail link

Reference Number: 934
Yasui T, Ohuchida K, Zhao M, Onimaru M, Egami T, Fujita H, Ohtsuka T, Mizumoto K, Tanaka M. Tumor-stroma interactions reduce the efficacy of adenoviral therapy through the HGF-MET pathway. Cancer Sci. 102, 484-91 (2011)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 1068
Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, Pasca di Magliano M, Simeone DM. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 141, 2218-2227.e5 (2011)
PubMed link      E-mail link

Reference Number: 1111
You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, Aftab DT, McDonald DM. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 71, 4758-68 (2011)
PubMed link      E-mail link

Reference Number: 1270
Hill KS, Gaziova I, Harrigal L, Guerra YA, Qiu S, Sastry SK, Arumugam T, Logsdon CD, Elferink LA. Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer. PLoS One. 7, e40420 (2012)
PubMed link      E-mail link

Reference Number: 1317
Sennino B, Ishiguro-Oonuma T, Schriver BJ, Christensen JG, McDonald DM. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res. 73, 3692-703 (2013)
PubMed link      E-mail link

Reference Number: 1372
Hage C, Rausch V, Giese N, Giese T, Schönsiegel F, Labsch S, Nwaeburu C, Mattern J, Gladkich J, Herr I. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis. 4, e627 (2013)
PubMed link      E-mail link

Reference Number: 1408
Avan A1, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell RJ, Lagerweij T, Van Tellingen O, Campani D, Fuchs D, Verheul HM, Schuurhuis GJ, Boggi U, Peters GJ, Würdinger T, Giovannetti E. Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. Cancer Res. 73, 6745-56 (2013)
PubMed link      E-mail link

Reference Number: 1629
Zhou W, Jubb AM, Lyle K, Xiao Q, Ong CC, Desai R, Fu L, Gnad F, Song Q, Haverty PM, Aust D, Grützmann R, Romero M, Totpal K, Neve RM, Yan Y, Forrest WF, Wang Y, Raja R, Pilarsky C, de Jesus-Acosta A, Belvin M, Friedman LS, Merchant M, Jaffee EM, Zheng L, Koeppen H, Hoeflich KP. PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. J Pathol. 234, 502-13 (2014)
PubMed link      E-mail link

Reference Number: 1736
Yan HH, Jung KH, Son MK, Fang Z, Kim SJ, Ryu YL, Kim J, Kim MH, Hong SS. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. Oncotarget. 5, 9150-68 (2014)
PubMed link      E-mail link

Reference Number: 1872
Chen HM, Tsai CH, Hung WC. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling. Oncotarget. 6, 14940-52 (2015)
PubMed link      E-mail link

Reviews

Reference Number: 1660
Delitto D, Vertes-George E, Hughes SJ, Behrns KE, Trevino JG. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. World J Gastroenterol. 20, 8458-70 (2014)
PubMed link      E-mail link

Reference Number: 1698
Fitzgerald TL, McCubrey JA. Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. Adv Biol Regul. 56, 45-50 (2014)
PubMed link      E-mail link